Armata appoints Dr. Deborah Birx as CEO, secures $25M credit from Innoviva

Armata Pharmaceuticals, Inc.

Dr. Deborah L. Birx appointed CEO and Board member; former Innoviva Board member and world-renowned healthcare leader.
New $25M credit agreement with Innoviva; existing convertible credit maturity extended to Jan 10, 2025.
Q2 loss from operations $(9.6)M; cash $12.5M at June 30, 2023; 36.1M shares outstanding.
Phase 2 inhaled AP-PA02 in NCFB enrolling; AP-SA02 bacteremia study advancing to Phase 2a in 3Q23.
$16.3M total grant funding from DoD/MTEC for AP-SA02 program.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Armata Pharmaceuticals, Inc. reported financial results for the quarter ended June 30, 2023.

Period: the quarter ended June 30, 2023
Result: reported results

Exact text from the filing

announced its financial results for the quarter ended June 30, 2023

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Armata Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-090888

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.